680 related articles for article (PubMed ID: 12881543)
21. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
Cohen-Jonathan Moyal E
Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of angiogenesis in the treatment of tumors.
Ostrowski K; Kinsner A
Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
[TBL] [Abstract][Full Text] [Related]
23. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic therapy and p53.
Hammond EM; Giaccia AJ
Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12142499
[No Abstract] [Full Text] [Related]
25. [Angiogenesis inhibitors and radiation therapy: concept and preliminary results].
Mazeron R; Bourhis J; Deutsch E
Bull Cancer; 2009 Mar; 96(3):299-310. PubMed ID: 19318308
[TBL] [Abstract][Full Text] [Related]
26. Interventions that induce modifications in the tumor microenvironment.
Bernhard EJ
Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567
[TBL] [Abstract][Full Text] [Related]
27. Antitumor interaction of short course endostatin and ionizing radiation.
Greenberger JS
Cancer J; 2000; 6(5):279-81. PubMed ID: 11079164
[No Abstract] [Full Text] [Related]
28. Inhibition of angiogenesis in cancer patients.
Verheul HM; Pinedo HM
Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.
Folkman J
Exp Cell Res; 2006 Mar; 312(5):594-607. PubMed ID: 16376330
[TBL] [Abstract][Full Text] [Related]
30. The fight against cancer: the next round.
Doherty M
Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
[No Abstract] [Full Text] [Related]
31. The combination of antiangiogenic therapy with other modalities.
O'Reilly MS
Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
[TBL] [Abstract][Full Text] [Related]
32. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
33. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
34. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy.
Mazeron R; Anderson B; Supiot S; Paris F; Deutsch E
Cancer Treat Rev; 2011 Oct; 37(6):476-86. PubMed ID: 21546163
[TBL] [Abstract][Full Text] [Related]
35. Vascular normalization: study examines how antiangiogenesis therapies work.
Webb T
J Natl Cancer Inst; 2005 Mar; 97(5):336-7. PubMed ID: 15741568
[No Abstract] [Full Text] [Related]
36. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
37. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
38. Novel agents target existing tumor vasculature.
Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
[No Abstract] [Full Text] [Related]
39. Closing in on cancer.
Park A
Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
[No Abstract] [Full Text] [Related]
40. Antiangiogenic agents in breast cancer.
Salter JT; Miller KD
Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
